perphenazine and Chronic Disease studies

Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

Excerpt	Relevance	Reference
"Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)."	9.15	Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011)
" Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)."	9.12	Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006)
"Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months."	9.12	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006)
"Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7."	9.12	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007)
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine."	9.06	Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989)
"The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period."	9.05	Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982)
"Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses."	6.79	Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014)
"Patients with DSM-IV-defined schizophrenia (N = 1,460) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of 4 second-generation drugs (olanzapine, quetiapine, risperidone, or ziprasidone) and followed for up to 18 months (phase 1)."	5.15	Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. ( Addington, DE; Davis, SM; Lieberman, JA; McEvoy, JP; Mohamed, S; Rosenheck, RA; Stroup, TS; Swartz, MS, 2011)
"Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment."	5.13	The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008)
" Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)."	5.12	Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006)
"Patients with schizophrenia (N=1,493) were assigned to treatment with a first-generation antipsychotic (perphenazine) or one of four second-generation drugs (olanzapine, quetia-pine, risperidone, or ziprasidone) and followed for up to 18 months."	5.12	Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. ( Davis, SM; Hsiao, JK; Keefe, RS; Leslie, DL; Lieberman, J; Lin, H; McEvoy, J; Miller, EA; Perkins, DO; Rosenheck, RA; Sindelar, J; Stroup, TS; Swartz, M, 2006)
"Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7."	5.12	Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007)
"Seventeen patients with acute schizophrenia and 30 with chronic schizophrenia were included in a randomized, double-blind parallel-group trial comparing sulpiride and perphenazine."	5.06	Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. ( Gordin, A; Koskinen, T; Lepola, U; Rimón, R; Salo, H, 1989)
"The efficacy of timiperone in schizophrenia as compared with perphenazine was assessed in a double-blind fashion in 205 patients throughout a 12-week treatment period."	5.05	Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. ( Asada, S; Inanaga, K; Nakano, S; Otsuki, S; Samejima, K; Sarai, K; Takahashi, R, 1982)
"Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses."	2.79	Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014)
" The average daily dosage was 81."	2.64	Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. ( Fensbo, C; Fruensgaard, K; Hansen, KM; Sihm, F; Wollenberg, J, 1978)
"Chronic mood disorders were also assessed using RDC criteria."	1.26	Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy. ( Prusoff, BA; Rounsaville, BJ; Sholomskas, D, 1980)

Research

Studies (41)

Authors

Clinical Trials (13)

Trial Overview

Trial Outcomes

Percent Weight Change Compared to Baseline Weight

BMI Percentile

BMI Z-scores

Weight Change

MATRICS Consensus Cognitive Battery Performance (MCCB)

Timeframe	Studies, this research(%)	All Research%
pre-1990	27 (65.85)	18.7374
1990's	2 (4.88)	18.2507
2000's	8 (19.51)	29.6817
2010's	4 (9.76)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Rosenheck, R	1
Lin, H	3
Mohamed, S	2
Rosenheck, RA	7
Swartz, M	2
McEvoy, J	2
Stroup, S	1
Fusar-Poli, RR	1
Stroup, TS	8
Lieberman, JA	7
McEvoy, JP	6
Davis, SM	7
Swartz, MS	6
Keefe, RS	5
Miller, AL	2
Hsiao, JK	6
Addington, DE	1
HOMBURGER, F	1
BARBOUR, JP	1
PETERSEN, PB	1
Perkins, DO	3
Davis, CE	1
Lebowitz, BD	1
Severe, J	1
Glick, ID	1
Shkedy, Z	1
Schreiner, A	1
Leslie, DL	1
Sindelar, J	1
Miller, EA	1
Lieberman, J	1
Capuano, G	1
Reimherr, F	2
McGee, MF	1
Capuano, GA	1
Belz, I	1
Wagner, HR	1
Swanson, JW	1
Miller, DD	1
McGee, M	1
Khan, A	1
Canive, JM	1
Takahashi, R	2
Inanaga, K	1
Samejima, K	1
Sarai, K	1
Asada, S	1
Otsuki, S	1
Nakano, S	1
Rounsaville, BJ	1
Sholomskas, D	1
Prusoff, BA	2
Ahlfors, UG	1
Dencker, SJ	1
Gravem, A	1
Remvig, J	2
Larsen, EB	1
Gerlach, J	2
Davis, JM	1
Gosenfeld, L	1
Tsai, CC	1
Obukhov, GA	1
Fruensgaard, K	1
Wollenberg, J	1
Hansen, KM	1
Fensbo, C	1
Sihm, F	1
Williams, DH	1
Weissman, MM	1
Astrachan, BM	1
Tegeler, J	1
Floru, L	1
Kistrup, K	1
Aaes-Jørgensen, T	1
Larsen, NE	1
Lepola, U	1
Koskinen, T	1
Rimón, R	1
Salo, H	1
Gordin, A	1
St Jean, A	1
Sterlin, C	1
Noe, W	1
Ban, TA	1
Prien, RF	1
Gillis, RD	1
Caffey, EM	1
Kramer, JC	1
Collins, AD	1
Dundas, J	1
Affleck, JW	1
Cooper, AJ	1
Forrest, AD	1
Smythies, JR	1
Zealley, AK	1
Becker, RE	1
Kellam, AM	1
Jones, KS	1
Uno, M	1
Petersson, H	1
Sorensen, B	1
Akimoto, H	1
Shimazaki, T	1
Shibata, N	1
Sato, Y	1
Yaryura-Tobias, JA	1
Wolpert, A	1
Dana, L	1
Merlis, S	1
Kampman, R	1
Leppäluoto, V	1
Rappaport, M	1
Brophy, JJ	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001]	Phase 4	1,600 participants	Interventional	2000-12-31	Completed
Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348]		1,110 participants (Actual)	Observational	2010-12-31	Completed
Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399]		60 participants (Actual)	Interventional	2021-10-25	Completed
Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124]	Phase 4	0 participants (Actual)	Interventional	2019-06-03	Withdrawn (stopped due to PI left institution prior to recruitment.)
A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167]	Phase 2	90 participants (Actual)	Interventional	2015-12-31	Completed
1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700]	Phase 4	14 participants (Actual)	Interventional	2013-07-31	Terminated (stopped due to very slow recruitment, no sufficient results)
Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684]	Phase 2	82 participants (Actual)	Interventional	2014-07-01	Completed
Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670]		10,347 participants (Actual)	Interventional	2016-01-20	Completed
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713]	Phase 2	260 participants (Actual)	Interventional	2012-06-30	Completed
Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis[NCT04368039]		20 participants (Anticipated)	Interventional	2019-12-04	Recruiting
E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia[NCT04756388]		90 participants (Anticipated)	Interventional	2021-02-01	Recruiting
Virtual Cognitive Behavioural Therapy for Psychosis: A Randomized Controlled Trial[NCT04752449]		60 participants (Anticipated)	Interventional	2021-02-01	Recruiting
Effects of Adding Transcranial Direct Current Stimulation to Executive Function Training for Schizophrenia-spectrum Disorders - a Randomized Control Trial[NCT05389345]		40 participants (Anticipated)	Interventional	2021-05-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of weight change (Mean)
Ziprasidone	11.58
Aripiprazole, Quetiapine, Risperidone	5.66

Intervention	BMI percentile (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	37.67	62.5
Ziprasidone	32	59

Intervention	BMI z-score (Mean)
	baseline	week 12 (n=1, n=2)
Aripiprazole, Quetiapine, Risperidone	-0.37	0.38
Ziprasidone	-0.51	0.22

Intervention	lbs (Mean)
	baseline	week 12 (n=1,2)
Aripiprazole, Quetiapine, Risperidone	118.5	141
Ziprasidone	120.5	151

The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

Prepulse Inhibition (PPI)

Intervention	standardized T-score (Mean)
	placebo	amphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo	57.870	56.000
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine	54.476	55.476
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo	39.895	38.105
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine	31.895	33.842

"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

Targeted Cognitive Training (TCT): PositScience, Inc.

Intervention	% inhibition of startle (Mean)
	Placebo	Amphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo	50.626	53.029
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine	50.626	45.822
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo	41.162	39.545
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine	22.629	32.656

"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours

Predicted Annual Rate of Change in 10 Year Risk of Fatal or Nonfatal Heart Attack or Stroke

Intervention	msec (Mean)
	placebo	amphetamine
Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo	-2.113	29.190
Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine	5.911	35.905
Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo	-50.158	101.000
Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine	-15.118	52.647

A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit

Intervention	percentage of annual rate of change (Number)
Prioritized Clinical Decision Support	14.2
Usual Care	20.8

Article	Year
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. The Journal of nervous and mental disease, 2014, Volume: 202, Issue:1 Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Admini	2014
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. The Journal of nervous and mental disease, 2015, Volume: 203, Issue:7 Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi	2015
Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia research, 2009, Volume: 107, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cloza	2009
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:1 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Comorbidity; Depression; Depressive	2011
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England journal of medicine, 2005, Sep-22, Volume: 353, Issue:12 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2005
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. International clinical psychopharmacology, 2006, Volume: 21, Issue:5 Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human	2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American journal of psychiatry, 2006, Volume: 163, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F	2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American journal of psychiatry, 2006, Volume: 163, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F	2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American journal of psychiatry, 2006, Volume: 163, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F	2006
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. The American journal of psychiatry, 2006, Volume: 163, Issue:12 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; F	2006
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz	2007
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. The American journal of psychiatry, 2007, Volume: 164, Issue:3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth	2007
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia research, 2008, Volume: 100, Issue:1-3 Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub	2008
Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. The Journal of international medical research, 1982, Volume: 10, Issue:4 Topics: Adolescent; Adult; Antipsychotic Agents; Butyrophenones; Chronic Disease; Clinical Trials as Topic;	1982
Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta psychiatrica Scandinavica. Supplementum, 1980, Volume: 279 Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Clopenthixol; Delayed-Action Preparations; D	1980
Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Current medical research and opinion, 1978, Volume: 5, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Dibenzoxazepines;	1978
Treatment of secondary depression in schizophrenia. A double-blind, placebo-controlled trial of amitriptyline added to perphenazine. Archives of general psychiatry, 1979, Volume: 36, Issue:5 Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Blood Pressure; Body Weight; Chronic Diseas	1979
Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. Acta psychiatrica Scandinavica, 1989, Volume: 80, Issue:1 Topics: Acute Disease; Adolescent; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Double-Blind Meth	1989
Clinical studies with propericiazine (R.P. 8909). Diseases of the nervous system, 1967, Volume: 28, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Association; Behavior; Chlorpromazine; Chronic Disease; Clin	1967
Butaperazine (Repoise). The Medical letter on drugs and therapeutics, 1968, Nov-01, Volume: 10, Issue:22 Topics: Chronic Disease; Clinical Trials as Topic; Haloperidol; Humans; Perphenazine; Phenothiazines; Pipera	1968
Intermittent pharmacotherapy in chronic schizophrenia. Hospital & community psychiatry, 1973, Volume: 24, Issue:5 Topics: Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Costs and Cost Analysis; Hospitals, Veter	1973
Treatment of chronic hallucinations with diazepam and phenothiazines. Diseases of the nervous system, 1967, Volume: 28, Issue:9 Topics: Adult; Auditory Perception; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Diazepam; Fem	1967
A double-blind trial of amitriptyline/perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. The British journal of psychiatry : the journal of mental science, 1967, Volume: 113, Issue:505 Topics: Adult; Affect; Amitriptyline; Analysis of Variance; Body Weight; Chronic Disease; Clinical Trials as	1967
Penicillamine and schizophrenia--a clinical trial. The British journal of psychiatry : the journal of mental science, 1969, Volume: 115, Issue:519 Topics: Acute Disease; Adult; Aged; Chronic Disease; Clinical Trials as Topic; Female; Humans; Male; Middle	1969
Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia. The American journal of psychiatry, 1970, Volume: 127, Issue:6 Topics: Adult; Aged; Amitriptyline; Chronic Disease; Clinical Trials as Topic; Female; Humans; Middle Aged;	1970
A double blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy. Acta psychiatrica Scandinavica, 1971, Volume: 47, Issue:2 Topics: Age Factors; Chronic Disease; Clinical Trials as Topic; Evaluation Studies as Topic; Female; Hospita	1971
Current status of pharmacotherapy in schizophrenia. Folia psychiatrica et neurologica japonica, 1966, Volume: 20, Issue:1 Topics: Adult; Chlorpromazine; Chronic Disease; Clinical Trials as Topic; Humans; Methotrimeprazine; Middle	1966

Article	Year
Clinical experiences and clinical trials. CNS spectrums, 2008, Volume: 13, Issue:6 Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine	2008
The NIMH-CATIE Schizophrenia Study: what did we learn? The American journal of psychiatry, 2011, Volume: 168, Issue:8 Topics: Antipsychotic Agents; Chronic Disease; Cost-Benefit Analysis; Drug Costs; Drug Substitution; Humans;	2011
Perphenazine as an antiemetic agent in cancer and other chronic diseases. Journal of the American Medical Association, 1958, Jul-05, Volume: 167, Issue:10 Topics: Antiemetics; Chronic Disease; Neoplasms; Perphenazine; Phenothiazines; Vomiting	1958
Maintenance therapy of chronic psychotics with perphenazine. The American journal of psychiatry, 1963, Volume: 120 Topics: Chronic Disease; Humans; Mental Disorders; Perphenazine; Psychotic Disorders	1963
[WITHDRAWAL OF PSYCHOPHARMACA AND RELAPSE IN SCHIZOPHRENICS]. Ugeskrift for laeger, 1964, Oct-08, Volume: 126 Topics: Chlorprothixene; Chronic Disease; Humans; Paranoid Disorders; Perphenazine; Recurrence; Schizophreni	1964
Chronic mood disorders in depressed outpatient--diagnosis and response to pharmacotherapy. Journal of affective disorders, 1980, Volume: 2, Issue:2 Topics: Adolescent; Adult; Affective Symptoms; Amitriptyline; Chronic Disease; Cyclothymic Disorder; Depress	1980
Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta psychiatrica Scandinavica, 1996, Volume: 93, Issue:5 Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Clopenthixol; Delayed-Action Preparations; Dyski	1996
[Prolonged action neuroleptics (review of the foreign literature)]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1975, Volume: 75, Issue:2 Topics: Acute Disease; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Child; Chronic Diseas	1975
[A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene (author's transl)]. Pharmakopsychiatrie, Neuro-Psychopharmakologie, 1979, Volume: 12, Issue:5 Topics: Chronic Disease; Delayed-Action Preparations; Fluspirilene; Humans; Perphenazine; Psychiatric Status	1979
Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology, 1991, Volume: 105, Issue:1 Topics: Adult; Chronic Disease; Dose-Response Relationship, Drug; Female; Flupenthixol; Humans; Male; Middle	1991
[Follow-up studies of schizophrenia]. Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica, 1971, Volume: 73, Issue:3 Topics: Adult; Catalepsy; Catatonia; Chlorpromazine; Chronic Disease; Convulsive Therapy; Depersonalization;	1971
[Chronic schizophrenia treated with depot perphenazine]. Nordisk psykiatrisk tidsskrift. Nordic journal of psychiatry, 1971, Volume: 25, Issue:4 Topics: Adult; Chronic Disease; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Male	1971
Action of L-Dopa in drug induced extrapyramidalism. Diseases of the nervous system, 1970, Volume: 31, Issue:1 Topics: Adult; Chlorpromazine; Chronic Disease; Dihydroxyphenylalanine; Extrapyramidal Tracts; Female; Human	1970
[Perphenazine enanthate in the treatment of chronic schizophrenia]. Duodecim; laaketieteellinen aikakauskirja, 1970, Volume: 86, Issue:20 Topics: Adult; Chronic Disease; Female; Humans; Male; Perphenazine; Schizophrenia	1970
Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. The Journal of nervous and mental disease, 1968, Volume: 146, Issue:5 Topics: Acute Disease; Adult; Attention; Auditory Perception; Chlorpromazine; Chronic Disease; Dextroampheta	1968
Single daily doses of neuroleptic drugs. Diseases of the nervous system, 1969, Volume: 30, Issue:2 Topics: Chlorpromazine; Chlorprothixene; Chronic Disease; Dosage Forms; Fluphenazine; Haloperidol; Humans; M	1969

perphenazine and Chronic Disease